The Alternative Summary Reporting Program

In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we discuss the recently announced cancellation of the FDA’s alternative summary reporting program, the reasons it existed, why it was cancelled, and what manufacturers will need to do going forward. Specifically, we address a number of questions, including:What is the alternative summary reporting program?Was the reporting of the “discovery” of this program fair or was it media hype?Why...